Intellipharmaceutics International Inc. (IPCI)

[fabius]

tilator, likely Lupin is well organized and much better managed than Mallinckrodt when it comes to generics.

I agree with you that generics should and could have been the solution for IPCI, giving them cash (and profits) enough to push ahead its high potential products.

The problem is IPCI is taking for ever to get their ANDAs approved, and its strategy is taking for ever to get a decent markat share once get approved.
So...they are not good at generics.

I am almost sure they got several CRL for their ANDAs, and they didn't inform investors accrodingly (likely passible of a lawsuit).

In september 2017 the said they were expecting two approvals by 2017 year end...they are just incapable of respect plans and expectations made by themself.

Now they have to CUT salaries and personnel...hope some activist will force the change